Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PolarityTE Inc. PTE

PolarityTE Inc is a commercial-stage biotechnology and regenerative biomaterials company. It's focused on transforming the lives of patients by discovering, designing and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement or regeneration of skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruct...


Recent & Breaking News (NDAQ:PTE)

PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

PR Newswire December 27, 2022

PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

PR Newswire November 10, 2022

PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

PR Newswire November 9, 2022

PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022

PR Newswire September 13, 2022

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

PR Newswire September 8, 2022

PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

PR Newswire August 11, 2022

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

PR Newswire August 1, 2022

PolarityTE Announces $8.0 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

PR Newswire June 6, 2022

PolarityTE to Attend H.C. Wainwright Global Investment Conference

PR Newswire May 23, 2022

PolarityTE to Effectuate 1-for-25 Reverse Stock Split

PR Newswire May 16, 2022

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update

PR Newswire May 16, 2022

PolarityTE Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE®

PR Newswire May 13, 2022

PolarityTE to Report Q1 2021 Financial Results on May 16, 2022

PR Newswire May 6, 2022

PolarityTE Announces First Subject Enrolled in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PR Newswire May 3, 2022

PolarityTE Reports Fiscal Year 2021 Financial Results and Provides Business Update

PR Newswire March 30, 2022

PolarityTE Announces Closing of $5.0 Million Registered Direct Offering

PR Newswire March 16, 2022

PolarityTE Announces $5.0 Million Registered Direct Offering

PR Newswire March 16, 2022

PolarityTE to Report Fiscal Year 2021 Financial Results on March 30, 2022

PR Newswire March 10, 2022

PolarityTE Announces Allowance of Fourth U.S. Patent

PR Newswire February 17, 2022

PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PR Newswire January 18, 2022